BIO, PhRMA Back Call For Fed. Circ. To Broaden AIA Estoppel
Two major drug industry groups urged the Federal Circuit Thursday to expand the reach of the America Invents Act inter partes review estoppel provision, arguing that lower courts have read it...To view the full article, register now.
Already a subscriber? Click here to view full article